Salspera is a privately held and privately funded, small biopharma company. Salspera is a clinical phase company seeking to change the treatment paradigm for patients faced with terminal, solid tumor cancers. Salspera's pipeline, highlighted by the lead program, Saltikva®, provides patients and oncologists with a novel immunotherapeutic option that has been shown to be highly effective and exceptionally safe.
Salspera's singular mission issue to bring this promising therapeutic and our other pipeline candidates to patients.
Salspera its managed by a team of highly experienced executives with broad experience in the biopharma industry. The management is supported by a cadre of some of the best advisors and consultants.
Eddie Moradian, PhD, Chief Executive Officer
Eddie Moradian is a graduate of the Swiss Federal Institute of Technology in Zurich, Switzerland. He has been an active entrepreneur, investor and operational chief executive of biotech companies involved in the life science research and early stage drug development sectors.
Daniel Saltzman, MD, PhD, Chief Medical Officer
Dan Saltzman, MD PhD is the originator of the technology platform which is the basis of Salspera today. He earned his MD and PhD degrees from the University of Minnesota and serves as the Chief of Pediatric Surgery and as Salspera's Chief Medical Officer. Dan has firsthand knowledge and experience with treating patients facing terminal diseases.
Advisors and Consultants
Salspera is supported by a large number of expert, professional consultants and advisors in matters including clinical trial monitoring, regulatory affairs, trial design and statistical analysis, data and safety monitoring